LEADER 01410nam  2200397   450 
001 9910707486603321
005 20160811084109.0
035   $a(CKB)5470000002464659
035   $a(OCoLC)956501056
035   $a(OCoLC)995470000002464659
035   $a(EXLCZ)995470000002464659
100   $a20160811d2006      ua             0
101 0 $aeng
135   $aurmn|||||||||
181   $2rdacontent
182   $2rdamedia
183   $2rdacarrier
200 10$aFDA's monitoring of postmarketing study commitments
210  1$a[Washington, D.C.] :$cDepartment of Health and Human Services, Office of Inspector General,$d2006.
215   $a1 online resource (iv, 38 pages) $cillustrations
300   $aTitle from title screen (viewed Aug 9, 2016).
300   $a"June 2006."
300   $a"OEI-01-04-00390."
320   $aIncludes bibliographical references (pages 23-28).
517 3 $aFood and Drug Administration's monitoring of postmarketing study commitments
517 1 $aFDA's monitoring of postmarketing study commitments
606   $aDrugs$zUnited States$xTesting
606   $aClinical trials$xGovernment policy$zUnited States
615  0$aDrugs$xTesting.
615  0$aClinical trials$xGovernment policy
801  0$bGPO
801  1$bGPO
906   $aBOOK
912   $a9910707486603321
996   $aFDA's monitoring of postmarketing study commitments$93304907
997   $aUNINA